Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06897683 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn if the Study Medicine Called Carbamazepine Changes How the Body Processes PF-07220060
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT06897683 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 14 participants.
The verdict
NCT06897683, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to learn how carbamazepine changes how the body processes PF-07220060 in the body of healthy adults. This study will happen in 2 periods. The purpose of Period 1 of the study is to understand how the medicine is changed and eliminated from the body after it is taken) and safety of a single dose of PF-07220060. The purpose of Period 2 of the study is to understand how the medicine is changed and eliminated from the body after it is taken and safety of a single dose of PF-07220060 following multiple days dosing carbamazepine twice a day. Multiple blood samples will be collected in each period up to 120 hours after the PF-07220060 dose in order to measure the amount of PF-07220060 in the blood. On Day 1 in Period 1, a single oral dose of PF-07220060 will be administered with food. Period 2 will begin following the last blood sample collection in Period 1. Carbamazepine will be dosed in Period 2 at 100 mg twice a day on Days 1, 2, and 3, and then, will increase to 200 mg twice a day on Days 4, 5, 6, and 7, and will eventually increase to and be maintained at 300 mg twice a day for the rest of Period 2 from Day 8 to Day 18. On Day 14 in Period 2, a single oral dose of PF-07220060 will be administered.
Interventions
- DRUG PF-07220060
- DRUG Carbamazepine ER Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2025-03-21 |
| Est. Completion | 2025-06-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06897683
The ClinicalTrials.gov registry entry for NCT06897683 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PF-07220060 is the first listed.
NCT06897683 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06897683 about?
NCT06897683 is a clinical study titled "A Study to Learn if the Study Medicine Called Carbamazepine Changes How the Body Processes PF-07220060". The purpose of this study is to learn how carbamazepine changes how the body processes PF-07220060 in the body of healthy adults. This study will happen in 2 periods. The purpose of Period 1 of the study is to understand how the medicine is changed and eliminated from the body after it is taken) an...
What is the current status of trial NCT06897683?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2025-03-21. Estimated completion is 2025-06-12.
What interventions are being tested in trial NCT06897683?
The interventions under investigation include: PF-07220060 (DRUG), Carbamazepine ER Tablet (DRUG).
Who is sponsoring clinical trial NCT06897683?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.